Online Stockmarket Trading Update

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The US$1.1 million contract is with an existing AtCor customer.

Duncan Ross, CEO of AtCor Medical said, “We are very pleased to win this important contract, which is AtCor’s fifth new engagement since US healthcare reform legislation was signed. These agreements confirm AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients.” Additional pharmaceutical contracts are being negotiated and are expected to close during the second half of the fiscal year. Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood pressure as an independent predictor and critical measurement. This mounting body of evidence helps to drive our sales to pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in assuring drug safety. It is equally important in patient care.”

AtCor Medical develops and markets products for the early detection of cardiovascular risk and  management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. AtCor has operations in Australia, the United States, and Europe.

www.atcormedical.com

http://www.traderdealer.com.au/Fundamentals/acg

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively announced that it has signed a new US$265,000 contract with a major international pharmaceutical company. This is an extension to an existing contract to supply SphygmoCor systems and clinical trials support services. A large portion of the contract value will be recognised in the current financial year.

During the past 120 days, AtCor has signed US$1.53m in new pharmaceutical contracts. The company has an ongoing pipeline of new business opportunities and anticipates additional pharmaceutical contracts in the current financial year.

“This contract extension has been awarded well in advance of contract expiration,” said Duncan Ross, CEO of AtCor Medical. “The new agreement demonstrates that AtCor’s growing reputation for high levels of customer satisfaction is being recognised through expanded business with long-term clients, and reinforces AtCor’s strong market position as the leading provider of non-invasive central blood pressure measurement in clinical trials.

With the US Healthcare Reform legislation now having been signed into law, the uncertainty as to key provisions and how they may affect the pharmaceutical industry has been clarified. AtCor expects this to translate into improved deal flow from this sector.

www.atcormedical.com

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new agreement with a major international pharmaceutical company to supply SphygmoCor systems and clinical trials support services. The US$955,000 contract is a new agreement with an existing AtCor customer. A large portion of the contract value will be recognised in the current financial year. AtCor has an ongoing pipeline of new business opportunities and anticipates additional pharmaceutical contracts in the current financial year.

“This is a significant contract, which confirms AtCor’s strong market position as the leading provider of noninvasive central blood pressure measurement in clinical trials. The new agreement demonstrates that AtCor’s growing reputation for high levels of customer satisfaction is being recognised through expanded business with long-term clients,” said Duncan Ross, CEO of AtCor Medical. “Scientific publications continue to reinforce the importance of using central blood pressure as a measurement,” Ross continued. “Using our SphygmoCor technology, the US National Institutes of Health (NIH) Strong Heart Study showed that increased central pressure is associated with cardiovascular risk. It found that when central pulse pressure rises above 50 mm Hg, patient risk of heart attack, stroke, and kidney disease nearly doubles while no such association was shown for brachial pulse pressure measurements taken at the arm. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in assuring drug safety. It is equally important in patient care.”

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe.

www.atcormedical.com